Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Who will win, Trump or Harris? The Dow predicts a 92% chance of winning the election.
The performance of the Dow before the election day 11 weeks, is related to whether the ruling party candidate has won the presidential election since 1968.
Obesity Drug Coverage Could Boost Spending By $35B Through 2034
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
(LLY) - Analyzing Eli Lilly's Short Interest
Lilly Sees IPR&D Charges Of About $2.83B On A Pre-Tax Basis
Eli Lilly Obesity Drug Shortage Ends Fueling Lawsuit Against FDA
10 Health Care Stocks Whale Activity In Today's Session
'Obesity Drugmaker Rivus Said To Weigh IPO As Soon As This Year; Co May Target Raising More Than $250M' - Bloomberg News
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
Regeneron Co-founder Warns of Harms From Weight-loss Drugs: FT
Can Novo, Lilly Take Credit for U.S. Obesity Rate Decline?
Trending Stocks This Week as Strong Jobs Report Underscore Resilience of U.S. Economy
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Futu Morning Post | Fund managers are entering the Chinese stock market at a record speed! The 'China Dragon' ETF lands in the US stock market; foreign capital accelerates its positions! Morgan Stanley increases its shareholding in BYD and other companies
The size of the USA money market fund has reached a record $6.46 trillion; Biden's vague stance has sparked an energy storm, causing international oil prices to soar by over 5%; just after raising funds, OpenAI secured a $4 billion credit line, with liquid assets exceeding over $10 billion.
US regulators said eli lilly and co's weight loss miracle drug is no longer in short supply, causing "平替" manufacturer Hims & Hers to drop nearly 10%.
FDA stated that eli lilly and co's two exenatide-containing GLP-1 injection Zepbound and Mounjaro have been in short supply since 2022 due to increased demand, but the shortage issue is now resolved. Industry organizations say that FDA's determination equals to pharmacies stopping the allocation and distribution of generic versions of the two drugs.
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Deutsche Bank Reiterates Buy on Eli Lilly, Maintains $1025 Price Target